Allergan, Inamed Smooth Out Concerns Over Reloxin

Law360, New York (May 14, 2007, 12:00 AM EDT) -- Botox marketer Allergan Inc. and Inamed Corp. have agreed to divest the rights to rival wrinkle buster Reloxin to alleviate concerns over the potential anti-competitive effects of their billion-dollar merger.

Allergan will sell off the rights to make and distribute Reloxin to resolve U.S. Federal Trade Commission’s charges that its $3.2 billion acquisition of Inamed would break antitrust laws, the FTC said Monday.

The FTC alleged that Allergan’s takeover of Inamed, which owns the rights to Reloxin, would add a few worry lines to competition regulators...
To view the full article, register now.